• Explore /
  • Poster
  • / Durability of responses with biweekly dosing of teclistamab in patients with relapsed/refractory multiple myeloma achieving a clinical response in the majesTEC-1 study.

Durability of responses with biweekly dosing of teclistamab in patients with relapsed/refractory multiple myeloma achieving a clinical response in the majesTEC-1 study.

Abstract Video & Slides Poster

Authors

Saad Usmani

Saad Zafar Usmani

Memorial Sloan Kettering Cancer Center, New York, NY

Saad Zafar Usmani , Lionel Karlin , Lotfi Benboubker , Hareth Nahi , Jesús San-Miguel , Danielle Trancucci , Keqin Qi , Tara Stephenson , Alfredo Perales-Puchalt , Katherine Chastain , Ajai Chari

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Plasma Cell Dyscrasia

Track

Hematologic Malignancies

Sub Track

Multiple Myeloma

Clinical Trial Registration Number

NCT03145181 and NCT04557098

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 8034)

DOI

10.1200/JCO.2023.41.16_suppl.8034

Abstract #

8034

Poster Bd #

26

Abstract Disclosures

Similar Posters

First Author: Niels W.C.J. van de Donk

First Author: Philippe Moreau

First Author: Robert M. Rifkin

First Author: Ross Firestone